Chemours (NYSE:CC) Stock Gets Price Target Cut from UBS Group

Chemours (NYSE:CC) had its price objective dropped by analysts at UBS Group from $16.00 to $15.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the specialty chemicals company’s stock. UBS Group‘s target price would suggest a potential upside of 9.00% from the company’s current price.

Other equities analysts have also recently issued reports about the company. Weiss Ratings cut Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, August 6th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $16.00 target price on shares of Chemours in a research note on Friday, October 9th. JPMorgan Chase & Co. reduced their price objective on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 13th. Morgan Stanley set a $18.00 price objective on shares of Chemours in a research note on Monday, August 10th. Finally, Zacks Research raised shares of Chemours from a “strong sell” rating to a “hold” rating in a research report on Thursday, September 10th. Three research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $17.45.

Chemours Stock Up 5.1%

CC traded up $0.67 during midday trading on Wednesday, reaching $13.76. 4,007,061 shares of the company were exchanged, compared to its average volume of 2,817,230. The company has a market cap of $2.07 billion, a price-to-earnings ratio of -13.49 and a beta of 1.47. Chemours has a one year low of $10.44 and a one year high of $28.67. The company’s fifty day moving average price is $14.12 and its 200 day moving average price is $18.25. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.88 and a current ratio of 1.66.

Chemours (NYSE:CC) last posted its earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). The company had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.53 billion. Chemours had a negative net margin of 2.64% and a positive return on equity of 78.76%. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.40 EPS. As a group, analysts expect that Chemours will post 0.83 EPS for the current year.

Insiders Place Their Bets

In other news, insider Calderon Gerardo Familiar bought 1,935 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was acquired at an average cost of $15.53 per share, with a total value of $30,050.55. Following the completion of the transaction, the insider directly owned 58,547 shares of the company’s stock, valued at $909,234.91. This represents a 3.42% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Denise Dignam acquired 3,378 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were acquired at an average cost of $14.95 per share, for a total transaction of $50,501.10. Following the completion of the acquisition, the chief executive officer owned 339,916 shares of the company’s stock, valued at approximately $5,081,744.20. The trade was a 1.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have purchased 8,663 shares of company stock valued at $130,601. Company insiders own 0.85% of the company’s stock.

Institutional Trading of Chemours

A number of institutional investors have recently modified their holdings of CC. BlackRock Inc. bought a new position in Chemours in the 2nd quarter worth approximately $477,769,000. Wolf Hill Capital Management LP purchased a new position in Chemours in the 2nd quarter valued at approximately $59,698,056. Bank of New York Mellon Corp bought a new stake in Chemours during the 2nd quarter valued at $33,353,000. Legal & General Group Plc bought a new stake in Chemours during the 2nd quarter valued at $28,400,000. Finally, Bank of America Corp DE lifted its position in shares of Chemours by 79.1% during the first quarter. Bank of America Corp DE now owns 1,317,003 shares of the specialty chemicals company’s stock worth $29,014,000 after acquiring an additional 581,621 shares in the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Chemours News Summary

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched Faizeon, a two-phase liquid-cooling solution targeting AI data centers, opening a potential growth avenue in a rapidly expanding market. Article: Chemours launches Faizeon cooling solutions
• Positive Sentiment: Fourth-quarter 2026 revenue guidance of $1.7 billion–$1.8 billion is above the cited $1.4 billion consensus. Full-year revenue guidance of $5.9 billion is in line with estimates. Article: Chemours provides earnings guidance
• Positive Sentiment: Truist lowered its price target to $18 from $20 but kept a Buy rating, indicating it still sees upside from the cited share price. Article: Truist price-target update
• Neutral Sentiment: UBS cut its target to $15 from $16 and maintained a Neutral rating, reflecting a more guarded outlook. Article: UBS adjusts Chemours price target
• Negative Sentiment: Third-quarter adjusted EPS of $0.21 missed the $0.26 consensus. Analysts also cited weak volumes and a cautious fourth-quarter outlook, keeping concerns about underlying demand in focus despite the revenue guidance. Article: Q3 results and outlook
• Negative Sentiment: Several law firms publicized a securities class action filed on behalf of investors who bought shares from February 20 to August 4, 2026. The suit alleges Chemours misrepresented Opteon refrigerant aftermarket demand, including distributor inventory timing; these claims are allegations, not established findings. The lead-plaintiff deadline is December 7, 2026, adding potential legal and reputational risk. Article: Chemours class-action reminder

About Chemours

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.